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Kidney diseases manifesting as proteinuria or elevated 
creatinine are increasingly prevalent complications 
of HIV infection. Today HIV-associated nephropathy 
(HIVAN) is a main cause of end-stage renal disease in 
HIV-infected African-Americans, and it is likely to be a 
result of a recently identified genetic predisposition based 
on polymorphisms of the myosin heavy-chain 9 (MYH9) 
gene.1 However, a variety of other histopathological 
renal diseases affect HIV-infected subjects of all ethnic 
groups.1 HIV-associated renal disease with overt 
proteinuria has been associated with poorer outcomes 
and increased mortality.2 Moreover, an increased rate of 
urinary albumin excretion, even in the micro-albuminuric 
range, is an indicator of glomerular damage and has 
been found to be associated with an increased risk 
of cardiovascular disease (CVD) and mortality in the 
general population.2 
The pathophysiological mechanisms underlying urinary 
albumin excretion and the increased risk of CVD are 
not fully understood. Both HIV-related and non-HIV-
related factors may play a role. There are few studies of 
albuminuria in HIV-infected patients, and most of these 
have been undertaken in selected small cohorts limited to 
the pre-combination antiretroviral therapy (cART) era. 
The renin-angiotensin system (RAS) is a major 
regulator of blood pressure and vascular response to 
injury. Continual activation of the RAS is associated 
with hypertension and end-organ damage, including 
renal disease and CVD. Inhibitors of the RAS have 
become a cornerstone for the treatment of hypertension. 
Use of these agents in patients with underlying renal 
disease has revealed that RAS inhibition exerts an 
anti-proteinuric effect independent of blood pressure 
reduction.3 Because RAS intervention can be targeted 
at various points, it has been postulated that combining 
more than one of these intervention points could lead to 
more effective inhibition of the RAS and a more robust 
decrement in protein excretion. Several studies support 
the use of combination therapy with angiotensin-
converting enzyme inhibitors (ACE-Is) and angiotensin 
receptor blockers (ARBs) in the general population,4 but 
there are no data on dual RAS blockade effects in HIV-
positive patients with proteinuria. 
CASE REPORT
A 45-year-old HIV-infected black African man (CDC A2) 
came to the Infectious Disease Clinic at SS Annunziata 
Hospital, Chieti, Italy, for follow-up. He had been treated 
with tenofovir + emtricitabine + efavirenz for one year 
at another centre in Italy. His personal history included 
multiple sexual partners, use of illegal injected drugs, 
tobacco smoking and chronic HCV infection. On 
admission the CD4+ level was 603 cells/µl, the CD4/
CD8 ratio 0.44, the HIV-RNA level <40 copies/ml, and 
the HCV-RNA level >5×105 copies/ml. Levels of the 
transaminases and glucose and lipid parameters were 
within normal limits, the glomerular filtration rate (GFR) 
assessed by the MDRD logarithmic model (MDRD-GFR) 
was 114 ml/min/173 m2, and the urinary albumin level 
was 1.5 g/l. The blood pressure (BP), measured with a 
mercury sphygmomanometer with an appropriately sized 
cuff after the patient had rested in a seated position, 
was elevated at 150/100 mmHg. Treatment with 10 
mg lercanidipine daily was started, strictly monitoring 
possible side-effects and interactions with cART. After 1 
month of antihypertensive therapy the BP had fallen to 
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120/90 mmHg without adverse effects, while the urinary 
albumin level and MDRD-GFR were 1.21 g/l and 106 ml/
min/173 m2, respectively. A change in cART, withdrawing 
tenofovir, was proposed, but the patient refused it. As a 
consequence, in spite of the improved mean BP (130/85 
mmHg), the albuminuria progressively worsened over 
the following months (to 2.52 g/l, with the MDRD-GFR 
rising to 117 ml/min/173 m2). The patient refused renal 
biopsy or cART changes. Administration of 300 mg 
irbesartan daily was then started in order to improve 
the renal dysfunction; after a month, while the BP and 
MDRD-GFR remained stable, the urinary albumin level 
had decreased only to 150 mg/dl. We therefore added 
lisinopril 20 mg/d to achieve dual blockade of the RAS. 
After 5 months the urinary albumin level had fallen to 
0.285 g/l without any change in BP, MDRD-GFR or viro-
immunological parameters (Fig. 1).
DISCUSSION
HIV infection is a strong risk factor for renal disease 
because of the presence of proteinuria, independent 
of other risk factors. Previously reported risk factors 
for HIV-related proteinuria include both traditional 
HIV-specific markers, such as CD4 lymphocyte count 
and HIV RNA levels, and several traditional renal and 
cardiovascular risk factors, such as higher systolic BP 
and insulin resistance. African-Americans, older people 
and those with a lower GFR and hepatitis C co-infection 
are also at increased risk.1 The potential nephrotoxicity 
induced by cART may considerably increase the risk 
of renal disease. Although previous studies of the 
longitudinal effects of cART on proteinuria are limited, 
certain frequently used antiretroviral medications such as 
tenofovir have been associated with acute renal failure. 
Moreover, there is increasing evidence that HIV-infected 
patients have hypertension requiring pharmacological 
treatment, which also represents an important risk factor 
for kidney disease. 
The choice of antihypertensive therapy for HIV-infected 
cART-treated patients must be made carefully. The 
classes of antihypertensive drugs that block the RAS, 
such as ACE-Is and ARBs, may be ideal. Several studies 
have reported beneficial effects of dual RAS blockade on 
kidney disease progression and proteinuria reduction in 
the general population. A more recent trial (IMPROVE)5 
has shown the effectiveness of fixed-dose combination 
ARB/ACE-I therapy in reducing albuminuria in non-HIV-
infected hypertensive subjects. It is therefore advisable 
to use combination ARB/ACE-I therapy in more complex 
cases to obtain a greater nephroprotective effect. 
Data on ACE-I and ARB use in HIV-infected patients 
are anecdotal,6 and there have been no well-designed 
studies on this subject to date. 
Our patient’s race was an additional problem in 
selecting effective antihypertensive therapy, because 
antihypertensive regimens that inhibit the RAS may be 
ineffective in black patients. In the African-American 
non-infected population, responsiveness to monotherapy 
with ACE-Is, ARBs and beta-blockers may be poorer 
than responsiveness to diuretics and calcium channel 
blockers (CCBs).7 In our patient dual RAS blockade 
therapy did not have substantial effects on BP control, 
while the main antihypertensive effect was achieved 
with the use of the CCB lercanidipine, in the absence 
of important interactions with cART. Lercanidipine did 
not improve proteinuria in our patient. This may indicate 
that HIV-related kidney disease is not only correlated 
with hypertension levels. The use of combined therapy 
with 20 mg lisinopril plus 300 mg irbesartan, obtaining a 
dual RAS blockade, produced a marked improvement in 
kidney function, with a -88% decrease from the baseline 
urinary albumin level.
CONCLUSION
This case shows that dual blockade of the RAS with 
combined ACE-I and ARB therapy reduced albuminuria 
in an HIV-infected black African patient. Furthermore, it 
indicates that the lowering of protein excretion brought 
about by dual RAS blockade is independent of BP 
reduction. Available data suggest that the beneficial 
effect achieved with combination therapy derives from 
more prolonged and complete inhibition of the RAS 
rather than from a physiological interaction between the 
ACE-I and the ARB.4 This more extensive RAS inhibition 
may provide incremental end-organ protection through 
its effects on chronic vascular responses to injury. 
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Fig. 1. Urinary albumin levels over the treatment period.
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